title: Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
authors.forename: Rosanne G
authors.initials: RG
authors.lastname: van Lingen
authors.forename: Piet E J
authors.initials: PE
authors.lastname: van Erp
authors.forename: Marieke M B
authors.initials: MM
authors.lastname: Seyger
authors.forename: Elke M G J
authors.initials: EM
authors.lastname: de Jong
authors.forename: Roelie T
authors.initials: RT
authors.lastname: de Boer-van Huizen
authors.forename: Rieke J B
authors.initials: RJ
authors.lastname: Driessen
authors.forename: Peter C M
authors.initials: PC
authors.lastname: van de Kerkhof
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001706:Biopsy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D005260:Female; D006801:Humans; D000069285:Infliximab; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4